TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and ...
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
According to an international multicenter study, CD2-negative mast cells are associated with significantly reduced overall survival in patients with SM. Patients with CD2-negative mast cells have ...
Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104Oral and Poster Presentations to Highlight Preclinical Data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results